Skip to Main Content

Related: Why are so few patients taking the new drugs for sickle cell?

Next year, two curative gene therapies could be approved for sickle cell disease. Yet drugmakers are pouring billions into developing new and more conventional drugs for the disease, even if they are likely to be far less transformative for individual patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment